Using leukemic cell lines and PDX models, we show here that combinatorial treatment using the pan‐HDACi Quisinostat is a promising approach to enhance treatment of ETV6::RUNX1+ BCP‐ALL when administered alongside Daunorubicin or Bortezomib. This evidence concerns the gene ETV6 and acute lymphoblastic leukemia.